# 177Lu-PSMA-I&T

Source: https://onco.cc/drugs/lu177-psma-it/  
OnCo record `lu177-psma-it` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

177Lu-PSMA-I&T is a second PSMA radioligand, chemically different from Pluvicto, that has passed two phase 3 trials on progression but has not yet shown a survival benefit.

## Summary

SPLASH (Lantheus PNT2002, ESMO 2024): rPFS 9.5 vs 6.0 months (HR 0.71) vs ARPI switch in taxane-naive mCRPC; interim OS HR 1.11 (immature, crossover). ECLIPSE (Curium, 7.4 GBq × 6): met rPFS endpoint vs ARPI in the same setting; OS maturing; FDA submission plan pending. Curium's Japanese registrational trial with PeptiDream started February 2026. Widely used off-protocol in Germany and Australia.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-06
- Code: PNT2002 (Lantheus); Curium 177Lu-PSMA-I&T
- Modality: Radioligand therapy (beta)
- Mechanism: Urea-based PSMA ligand with DOTAGA chelator carrying 177Lu; beta emission.

## Sources

- SPLASH primary analysis (Lantheus, ESMO 2024): https://lantheusholdings.gcs-web.com/news-releases/news-release-details/lantheus-presents-results-primary-analysis-phase-3-pivotal
- ECLIPSE meets rPFS (OncLive): https://www.onclive.com/view/177lu-psma-i-t-meets-rpfs-end-point-in-psma-mcrpc

## Connected records

- cancers: [Metastatic castration-resistant prostate cancer](https://onco.cc/cancers/prostate-mcrpc/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- technologies: [PSMA PET](https://onco.cc/technologies/psma-pet/), [Radioligand therapy (beta emitters)](https://onco.cc/technologies/radioligand-therapy/), [Radiopharmaceutical GMP and releasing a drug that decays](https://onco.cc/technologies/radiopharmaceutical-gmp-release/), [Research reactors for medical isotopes (Mo-99, Lu-177, I-131)](https://onco.cc/technologies/research-reactor-isotope-production/)
- targets: [PSMA](https://onco.cc/targets/psma/)
- companies: [Curium](https://onco.cc/companies/curium/), [Lantheus](https://onco.cc/companies/lantheus/)
- trials: [ECLIPSE](https://onco.cc/trials/eclipse-psma/), [SPLASH](https://onco.cc/trials/splash/)
- people: [Peter Bartenstein](https://onco.cc/people/peter-bartenstein/)
- biomarkers: [PSMA expression by PET (PSMA-positive)](https://onco.cc/biomarkers/psma-pet-expression/)

---
JSON: https://onco.cc/api/v1/entities/lu177-psma-it.json